Your browser doesn't support javascript.
loading
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
Hao, Yue; Yu, Xinchao; Bai, Yonghong; McBride, Helen J; Huang, Xin.
Afiliação
  • Hao Y; Department of Molecular Engineering, Amgen Inc., Cambridge, MA, United States of America.
  • Yu X; Amgen Postdoctoral Fellow Program, Cambridge, MA, United States of America.
  • Bai Y; Department of Molecular Engineering, Amgen Inc., South San Francisco, CA, United States of America.
  • McBride HJ; Department of Molecular Engineering, Amgen Inc., Cambridge, MA, United States of America.
  • Huang X; Biosimilars, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, United States of America.
PLoS One ; 14(5): e0216095, 2019.
Article em En | MEDLINE | ID: mdl-31042744
ABSTRACT
Trastuzumab and pertuzumab are monoclonal antibodies that bind to distinct subdomains of the extracellular domain of human epidermal growth factor receptor 2 (HER2). Adding these monoclonal antibodies to the treatment regimen of HER2-positive breast cancer has changed the paradigm for treatment in that form of cancer. Synergistic activity has been observed with the combination of these two antibodies leading to hypotheses regarding the mechanism(s) and to the development of bispecific antibodies to maximize the clinical effect further. Although the individual crystal structures of HER2-trastuzumab and HER2-pertuzumab revealed the distinct binding sites and provided the structural basis for their anti-tumor activities, detailed structural information on the HER2-trastuzumab-pertuzumab complex has been elusive. Here we present the cryo-EM structure of HER2-trastuzumab-pertuzumab at 4.36 Å resolution. Comparison with the binary complexes reveals no cooperative interaction between trastuzumab and pertuzumab, and provides key insights into the design of novel, high-avidity bispecific molecules with potentially greater clinical efficacy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Trastuzumab Limite: Female / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Trastuzumab Limite: Female / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos